Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Shanghai Henlius and Organon’s pertuzumab biosimilar met phase 3 trial goals, and the FDA accepted an application for their denosumab biosimilar; Meitheal Pharmaceuticals expanded its US biosimilars lineup; Celltrion USA’s analysis of Zymfentra (subcutaneous infliximab) showed comparable efficacy and safety between monotherapy and combination therapy for inflammatory bowel disease, supporting monotherapy as a viable option.
Shanghai Henlius Biotech and Organon Updates
Partners Shanghai Henlius Biotech and Organon announced that the phase 3 clinical trial for the investigational biosimilar HLX11, a pertuzumab biosimilar, met its primary end point.1
Henlius granted Organon global commercialization rights (excluding China) for HLX11 under a 2022 license and supply agreement. The trial (NCT05346224) compared HLX11 with Perjeta as a neoadjuvant therapy for HER2-positive, hormone receptro–negative early or locally advanced breast cancer, alongside trastuzumab and docetaxel.
Patients received treatment every 3 weeks for 4 cycles, and the primary end point—total pathological complete response rate—was achieved. Secondary end points, including safety and pharmacokinetics, are still being analyzed. Pertuzumab is already approved for use with trastuzumab and chemotherapy in various regions for treating advanced HER2-positive breast cancer.
Additionally, the companies announced that the FDA accepted the biologic license application for HLX14, a biosimilar to denosumab (Prolia/Xgeva), used to treat osteoporosis in postmenopausal women at high risk for fractures.2
Under the aforementioned 2022 agreement, Organon holds exclusive commercialization rights for HLX14 in the US, European Union (EU), and Canada. The application is supported by extensive studies: a phase 1 study in Chinese male subjects to establish pharmacokinetic similarities and a global phase 3 trial demonstrating HLX14's efficacy, safety, and immunogenicity compared to EU-sourced Prolia in postmenopausal women with osteoporosis.
Meitheal Signs Deal for US Biosimilars
Meitheal Pharmaceuticals has expanded its biosimilars portfolio through an exclusive licensing agreement with its parent company, Hong Kong King-Friend Industry.3 This agreement grants Meitheal the rights to market and distribute 3 biosimilars in the US: a pegfilgrastim, a filgrastim, and a follitropin alpha.
The first 2 are oncology medications for supporting white blood cell production during cancer treatment to prevent febrile neutropenia. Follitropin alpha, a recombinant form of human follicle-stimulating hormone (FSH), addresses a significant unmet need in the US fertility market, which saw $847 million in branded FSH sales in 2023. With no existing biosimilar alternatives for follitropin alpha, the product offers an affordable option for fertility patients.
Meitheal’s parent company has invested over $300 million to bolster product supply and research, including $30 million in a monoclonal antibody facility. With these additions, Meitheal’s biosimilars portfolio now totals 8 treatments.
Zymfentra Data Through 102 Weeks
Celltrion USA presented a post hoc analysis of the LIBERTY-CD and LIBERTY-UC studies for Zymfentra (infliximab-dyyb), the world’s first subcutaneous infliximab product, at the 2024 American College of Gastroenterology Annual Meeting.4
This analysis found comparable clinical outcomes for patients with inflammatory bowel disease (IBD) treated with Zymfentra as monotherapy versus combination therapy with immunosuppressants, indicating that monotherapy may be a viable option. Zymfentra, the only FDA-approved subcutaneous infliximab, had previously shown significant efficacy over placebo for maintenance in IBD.
The analysis included 429 patients with IBD and showed similar efficacy and safety profiles between monotherapy and combination therapy up to Week 102, though combination therapy generally resulted in higher mean infliximab levels.
Results showed that monotherapy achieved similar clinical outcomes to combination therapy at weeks 54 and 102, suggesting it could be an effective option without the added immunosuppressant. While combination therapy generally had higher infliximab trough levels after week 10, both approaches demonstrated comparable safety profiles, highlighting Zymfentra monotherapy as a potential choice for IBD patients aiming to minimize medication burden.
"The new data strengthens the case for Zymfentra monotherapy as a potential treatment option for patients with Crohn's disease and ulcerative colitis," said Hetal Patel, PharmD MBA, head of medical affairs at Celltrion USA. “These findings suggest that Zymfentra could offer flexibility in treatment approaches, providing confidence in monotherapy as an alternative to combination therapy, while maintaining effective disease control."
References
1. Primary endpoint met in phase 3 comparative clinical study of Perjeta (pertuzumab) biosimilar candidate HLX11. Organon. News release; September 30, 2024. Accessed November 4, 2024. https://www.organon.com/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-pertuzumab-biosimilar-candidate-hlx11/
2. US fda accepts biologics license application (BLA) for HLX14, biosimilar candidate of Prolia/Xgeva (denosumab). Organon. News release; October 30, 2024. Accessed November 4, 2024. https://www.organon.com/news/us-fda-accepts-biologics-license-application-bla-for-hlx14-biosimilar-candidate-of-prolia-xgeva-denosumab/
3. Meitheal Pharmaceuticals secures exclusive commercial licensing agreement for three biosimilars in the U.S. Meitheal Pharmaceuticals. News release; October 31, 2024. Accessed November 4, 2024. https://www.meithealpharma.com/news/90
4. Celltrion presents post hoc analysis of LIBERTY studies of Zymfentra (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting. Celltrion USA. News release; October 30, 2024. Accessed November 4, 2024. https://en.prnasia.com/releases/global/celltrion-presents-post-hoc-analysis-of-liberty-studies-of-zymfentra-infliximab-dyyb-at-the-american-college-of-gastroenterology-2024-annual-scientific-meeting-466440.shtml
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.